Drug Trial Radar · NCT02463032
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
Last checked: Nov 19, 2026Latest source record: Dec 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
136
Actual
Start
Aug 2015
Primary completion
Mar 2019
Study completion Mar 2019
Sponsor
- Lead sponsor
- GTxIndustry
- Sponsor type
- Industry
- First posted
- Jun 4, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is effective and safe in the treatment of patients with metastatic or locally advanced Estrogen Receptor (ER)+ and Androgen Receptor (AR)+ breast cancer in postmenopausal women.
Conditions
- ER+ and AR+ Breast Cancer
Interventions
GTx-024Drug
To determine whether either or both doses result in an acceptable clinical benefit rate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ SubjectsTime frame: 24 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Holy Cross Hospital
Fort Lauderdale, Florida
Dana Farber Cancer Institute
Boston, Massachusetts
St. Vincent Frontier Cancer Center
Billings, Montana
The West Clinic, PC
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.